8A-PDHQ

8A-PDHQ

8A-PDHQ

Chemical compound

8a-Phenyldecahydroquinoline (8A-PDHQ) is a high affinity NMDA antagonist developed by a team at Parke Davis in the 1950s.[1] It is a structural analog of phencyclidine with slightly lower binding affinity than the parent compound. (−)-8a-Phenyldecahydroquinoline has an in vivo potency comparable to that of (+)-MK-801.[2][3]

Quick Facts Identifiers, CAS Number ...

References

  1. [1]
    US Patent 3035059
  2. [2]
    Chen C, Kozikowski AP, Wood PL, Reynolds IJ, Ball RG, Pang YP (May 1992). "Synthesis and biological activity of 8a-phenyldecahydroquinolines as probes of PCP's binding conformation. A new PCP-like compound with increased in vivo potency". Journal of Medicinal Chemistry. 35 (9): 1634–8. doi:10.1021/jm00087a020. PMID 1315871.
  3. [3]
    Elhallaoui M, Laguerre M, Carpy A, Ouazzani FC (February 2002). "Molecular modeling of noncompetitive antagonists of the NMDA receptor: proposal of a pharmacophore and a description of the interaction mode". Journal of Molecular Modeling. 8 (2): 65–72. doi:10.1007/s00894-001-0067-4. PMID 12032600. S2CID 34882820.


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article 8A-PDHQ, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.